A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer
This clinical trial evaluated the safety and pharmacokinetics of F-627 as an adjuvant to chemotherapy in female breast cancer patients undergoing myelotoxic chemotherapy. The study was conducted by EVIVE Biotechnology in collaboration with Fudan University, involving 18 patients across three dose cohorts.
Indication: Neutropenia
Modality: small molecule
Target: F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)
Sponsor: EVIVE Biotechnology
Source URL: ClinicalTrials.gov
Source updated: Feb 23, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)
View original source fields
Condition raw: Neutropenia
Condition normalized: Neutropenia
Modality raw: Neutropenia
Modality normalized: small molecule
Target raw: F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)
Target normalized: F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)